Sigma 1 Receptor Agonists For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Property | Value | [1]
|----------|-------| [2]
| Category | Neuroprotection | [3]
| Target | Sigma-1 Receptor (SIGMAR1) | [4]
| Drug Class | Small molecule agonists | [5]
| Diseases | Alzheimer's Disease, Parkinson's Disease, ALS, Huntington's Disease, Stroke | [6]
| Status | Preclinical and early clinical trials | [7]
The Sigma-1 Receptor (SIGMAR1) is a chaperone protein located in the endoplasmic reticulum (ER) that plays a critical role in cellular homeostasis. Sigma-1 agonists provide neuroprotection through multiple mechanisms:
| Drug | Class | Stage | Notes |
|---|---|---|---|
| Pridopidine | Small molecule | Phase 3 (HD) | Developed for Huntington's disease |
| Fluvoxamine | SSRI | Approved | Has sigma-1 agonist activity |
| Donepezil | ChEI | Approved | Has sigma-1 activity |
| SA-4503 | Small molecule | Preclinical | Selective sigma-1 agonist |
| PRE-084 | Small molecule | Preclinical | Selective sigma-1 agonist |
Pridopidine is the most advanced Sigma-1 receptor agonist for neurodegeneration:
The study of Sigma 1 Receptor Agonists For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Nguyen L, et al. "Sigma-1 receptor agonists as therapeutic drugs for ALS." Expert Opin Investig Drugs. 2021. ↩︎
Francardo V, et al. "Sigma-1 receptor agonists in Parkinson's disease." Neuropharmacology. 2019. ↩︎
Ryskamp D, et al. "Sigma-1 receptor protects from Alzheimer's disease." J Alzheimers Dis. 2019. ↩︎
Sahlholm K, et al. "Pridopidine for Huntington's disease." Expert Opin Pharmacother. 2020. ↩︎
Ghadiri T, et al. "Sigma-1 receptor in stroke and neuroprotection." Stroke. 2020. ↩︎
Mori T, et al. "Sigma-1 receptors in neurodegenerative diseases." Adv Exp Med Biol. 2020. ↩︎
Woeffle K, et al. "Fluvoxamine and sigma-1 receptors." Psychopharmacology (Berl). 2021. ↩︎